Advertisement

Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae

  • Paolo GaibaniEmail author
  • Donatella Lombardo
  • Michele Bartoletti
  • Simone Ambretti
  • Caterina Campoli
  • Maddalena Giannella
  • Sara Tedeschi
  • Matteo Conti
  • Rita Mancini
  • Maria Paola Landini
  • Maria Carla Re
  • Pierluigi Viale
  • Russell E. Lewis
Original Article

Abstract

Combination therapies are frequently used in the treatment of multidrug-resistant Klebsiella pneumoniae infection without consensus regarding which combination is the most effective. We compared bactericidal titres from sera collected from critically ill patients receiving meropenem plus tigecycline (n = 5), meropenem plus colistin (n = 5), or meropenem, colistin and tigecycline (n = 5) against K. pneumoniae isolates that included ESBL-producing (n = 7) and KPC-producing strains (n = 14) with varying sensitivity patterns to colistin and tigecycline. Meropenem concentrations (Cmin) were measured in all samples by LC-MS/MS, and indexed to respective pathogen MICs to explore differences in patterns of bactericidal activity for two versus three drug combination regimens. All combination regimens achieved higher SBTs against ESBL (median reciprocal titre 128, IQR 32–256) versus KPC (4, IQR 2–32) strains. Sera from patients treated with meropenem-colistin yielded higher median SBTs (256, IQR 64–512) than either meropenem-tigecycline (32, IQR 8–256; P < 0.001). The addition of tigecycline was associated with a lower probability of achieving a reciprocal SBT above 8 when meropenem concentrations were below the MIC (P = 0.04). Although the clinical significance is unknown, sera from patients receiving tigecycline-based combination regimens produce lower serum bactericidal titres against ESBL or KPC-producing K. pneumoniae. SBTs may represent a useful complimentary endpoint for comparing pharmacodynamics of combinations regimens for MDR Enterobacteriaceae.

Keywords

Klebsiella pneumoniae Serum bactericidal assay ESßL KPC Tigecycline 

Notes

Acknowledgements

We would like to thank the patients, nurses, and medical residents and technicians who donated their time and energy to complete this study.

Funding

This work was partially supported by the Italian Ministry of Health (Ricerca Finalizzata, Giovani Ricercatori, GR-2018-12367572) and the Emilia-Romagna region.

Compliance with ethical standards

Conflict of interest

Russell Lewis has received research funding support from Gilead Inc., Pfizer, and served on speakers or advisory boards for Merck & Co. Inc., and Gilead.

All others declare no interests.

Ethical approval

The study design was approved by the Institutional Research Committee.

Supplementary material

10096_2019_3628_MOESM1_ESM.docx (2.7 mb)
ESM 1 (DOCX 2720 kb)

References

  1. 1.
    Pitout JDD, Nordmann P, Poirel L (2015) Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873–5884.  https://doi.org/10.1128/AAC.01019-15 CrossRefGoogle Scholar
  2. 2.
    Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, S panu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943–950.  https://doi.org/10.1093/cid/cis588 CrossRefGoogle Scholar
  3. 3.
    Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328.  https://doi.org/10.1128/AAC.02166-13 CrossRefGoogle Scholar
  4. 4.
    Falcone M, Russo A, Iacovelli A, Restuccia G, Ceccarelli G, Giordano A, Farcomeni A, Morelli A, Venditti M (2016) Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect 22:444–450.  https://doi.org/10.1016/j.cmi.2016.01.016 CrossRefGoogle Scholar
  5. 5.
    Giannella M, Trecarichi EM, Giacobbe DR, De Rosa FG, Bassetti M, Bartoloni A, Bartoletti M, Losito AR, Del Bono V, Corcione S, Tedeschi S, Raffaelli F, Saffioti C, Spanu T, Rossolini GM, Marchese A, Ambretti S, Cauda R, Viscoli C, Lewis RE, Viale P, Tumbarello M (2018) Italian study group on resistant infections of the Società Italiana Terapia Antinfettiva (ISGRI-SITA). Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents 51:244–248.  https://doi.org/10.1016/j.ijantimicag.2017.08.019 CrossRefGoogle Scholar
  6. 6.
    Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, De Gasperi A, Mularoni A, Tascini C, Parruti G, Pallotto C, Sica S, Concia E, Cultrera R, De Pascale G, Capone A, Antinori S, Corcione S, Righi E, Losito AR, Digaetano M, Amadori F, Giacobbe DR, Ceccarelli G, Mazza E, Raffaelli F, Spanu T, Cauda R, Viale P (2019) Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis 68:355–364.  https://doi.org/10.1093/cid/ciy492 CrossRefGoogle Scholar
  7. 7.
    Watkins RR, Deresinski S (2015) Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care? Expert Rev Anti-Infect Ther 13:405–407.  https://doi.org/10.1586/14787210.2015.1018825 Google Scholar
  8. 8.
    Stratton CW (1988) Serum bactericidal test. Clin Microbiol Rev 1:19–26CrossRefGoogle Scholar
  9. 9.
    Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, Ambretti S (2014) In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 69:1856–1865.  https://doi.org/10.1093/jac/dku065 CrossRefGoogle Scholar
  10. 10.
    Clinical Laboratory Standards Insititute (1999) M21A-methodology for the serum bactericidal test: approved guideline. Clinical Laboratory Standards Institute, WayneGoogle Scholar
  11. 11.
    Ocampo PS, Lazar V, Papp B, Arnoldini M, Abel zur Wiesch P, Busa-Fekete R, Fekete G, Pál C, Ackermann M, Bonhoeffer S (2014) Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob Agents Chemother 58:4573–4582CrossRefGoogle Scholar
  12. 12.
    Bi S, Yao X, Huang C, Zheng X, Xuan T, Sheng J, Xu K, Zheng B, Yang Q (2019) Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection. Infection.  https://doi.org/10.1007/s15010-019-01274-w
  13. 13.
    Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, Tsakris A (2011) Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assay. Int J Antimicrob Agents 37:244–247.  https://doi.org/10.1016/j.ijantimicag.2010.10.031 CrossRefGoogle Scholar
  14. 14.
    Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL (2011) In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 55:1420–1427.  https://doi.org/10.1128/AAC.01253-10 CrossRefGoogle Scholar
  15. 15.
    Michail G, Labrou M, Pitiriga V, Manousaka S, Sakellaridis N, Tsakris A, Pournaras S (2013) Activity of tigecycline combinations with colistin, meropenem, rifampin and gentamicin against KPC-producing Enterobacteriaceae in a murine thigh model. Antimicrob Agents Chemother 57:6028–6033.  https://doi.org/10.1128/AAC.00891-13 CrossRefGoogle Scholar
  16. 16.
    Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS (2014) Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 44:1–7.  https://doi.org/10.1016/j.ijantimicag.2014.01.006 CrossRefGoogle Scholar
  17. 17.
    Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A (2018) Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and CARBAPENEMASE-producing Enterobacteriaceae. Clin Microbiol Rev 31:e00079–e00017.  https://doi.org/10.1128/CMR.00079-17 CrossRefGoogle Scholar
  18. 18.
    Xie J, Roberts JA, Alobaid AS, Roger C, Wang Y, Yang Q, Sun J, Dong H, Wang X, Xing J, Lipman J, Dong Y (2017) Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. Antimicrob Agents Chemother 61:e00345–e00317.  https://doi.org/10.1128/AAC.00345-17 CrossRefGoogle Scholar
  19. 19.
    Dixit D, Madduri RP, Sharma R (2014) The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti-Infect Ther 12:397–400.  https://doi.org/10.1586/14787210.2014.894882 CrossRefGoogle Scholar
  20. 20.
    Meletiadis J, Stergiopoulou T, O'Shaughnessy EM, Peter J, Walsh TJ (2007) Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob Agents Chemother 51:2053–2064CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Paolo Gaibani
    • 1
    Email author
  • Donatella Lombardo
    • 1
  • Michele Bartoletti
    • 2
    • 3
  • Simone Ambretti
    • 1
  • Caterina Campoli
    • 2
  • Maddalena Giannella
    • 2
    • 4
  • Sara Tedeschi
    • 2
  • Matteo Conti
    • 4
  • Rita Mancini
    • 4
  • Maria Paola Landini
    • 1
    • 3
    • 5
  • Maria Carla Re
    • 1
    • 3
  • Pierluigi Viale
    • 2
    • 3
  • Russell E. Lewis
    • 2
    • 4
  1. 1.Operative Unit of Clinical Microbiology, Regional Reference Centre for Microbiological EmergenciesS.Orsola-Malpighi University HospitalBolognaItaly
  2. 2.Department of Medical Sciences and Surgery, Operative Unit of Infectious DiseasesS.Orsola-Malpighi University HospitalBolognaItaly
  3. 3.University of BolognaBolognaItaly
  4. 4.Central LaboratoryS. Orsola-Malpighi University HospitalBolognaItaly
  5. 5.Istituto Ortopedico RizzoliBolognaItaly

Personalised recommendations